Loading clinical trials...
Loading clinical trials...
Phase 1b Open-label Study of MK-8353 in Combination With Selumetinib (MK-5618) in Participants With Advanced/Metastatic Solid Tumors
Conditions
Interventions
MK-8353
Selumetinib
Locations
5
United States
Florida Cancer Specialists ( Site 7000)
Sarasota, Florida, United States
Next Oncology ( Site 0001)
San Antonio, Texas, United States
BC Cancer-Vancouver Center ( Site 0011)
Vancouver, British Columbia, Canada
Princess Margaret Cancer Centre ( Site 0012)
Toronto, Ontario, Canada
Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 0020)
Bellinzona, Canton Ticino, Switzerland
Start Date
February 22, 2019
Primary Completion Date
March 19, 2021
Completion Date
March 19, 2021
Last Updated
July 27, 2023
NCT04570423
NCT06926283
NCT07177937
NCT07489378
NCT07181681
NCT07387068
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions